+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Acute Respiratory Distress Syndrome Drug"

From
From
From
Acute Respiratory Distress Syndrome (ARDS) Market Report 2025 - Product Thumbnail Image

Acute Respiratory Distress Syndrome (ARDS) Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
From
Acute Respiratory Distress Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Acute Respiratory Distress Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 180 Pages
  • Global
From
Acute Respiratory Distress Syndrome Treatment Market 2025-2029 - Product Thumbnail Image

Acute Respiratory Distress Syndrome Treatment Market 2025-2029

  • Report
  • January 2025
  • 193 Pages
  • Global
From
From
From
ARDS - Epidemiology Forecast to 2032 - Product Thumbnail Image

ARDS - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
  • 13 Results (Page 1 of 1)
Loading Indicator

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition that affects the lungs and can lead to respiratory failure. Treatment for ARDS typically involves the use of respiratory drugs, such as bronchodilators, corticosteroids, and antibiotics. These drugs are used to reduce inflammation, improve oxygenation, and reduce the risk of infection. In addition, supportive care, such as mechanical ventilation, is often necessary to help patients with ARDS recover. The ARDS drug market is highly competitive, with a number of companies offering a range of products. These include pharmaceutical companies, such as GlaxoSmithKline, Merck, and Pfizer, as well as biotechnology companies, such as Amgen and Biogen. Additionally, there are a number of generic drug manufacturers that offer lower-cost alternatives to branded drugs. Show Less Read more